← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #938 OF 1,000 MOST-CITED

Protection from external factors

FDA cited this observation 18 times across 18 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs18
BY FISCAL YEAR
FY20261
FY20251
FY20233
FY20222
FY20201
FY20191
FY20181
FY20173
FY20165

How FDA worded it — real examples

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Coupler LLC · West Chester, Pennsylvania · Drugs · 2026-03-02

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Wells Pharmacy, Inc · Dyersburg, Tennessee · Drugs · 2025-04-25

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Regenerative Processing Plant, LLC · Palm Harbor, Florida · Drugs · 2023-06-30

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Neobiosis LLC · Gainesville, Florida · Drugs · 2023-02-21

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Denison Pharmaceuticals, LLC · Lincoln, Rhode Island · Drugs · 2023-02-09

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

US Specialty Formulations LLC · Allentown, Pennsylvania · Drugs · 2022-04-26

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →